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A Proposed Framework for
Assessing Risks to Children
Over the past decade a dramatic increase has
occurred in the recognition and concern for
children as a potentially susceptible popula-
tion for exposure to toxic environmental
agents. The U.S. federal government has
developed and implemented many new poli-
cies and programs to assess and reduce envi-
ronmental risks to children. As the body of
knowledge on children’s health and risk fac-
tors expands rapidly, there is an increasing
need for the systematic application of this
knowledge on children in the risk assess-
ment process. The evaluation of children’s
health risks from environmental exposures
should be structured, informed, and guided
by the best available information on the
many factors influencing children’s expo-
sures (e.g., activity patterns, diet, physiol-
ogy) and sensitivities (e.g., toxicokinetics
and toxicodynamics). This kind of informa-
tion needs to be organized and presented in
a format that focuses on its application to
risk assessment.
In July–August 2001 the International
Life Sciences Institute (ILSI) Risk Science
Institute (RSI) held a workshop to begin to
address these needs [see Olin and Sonawane
(2003) for a complete list of workshop
participants]. The objective of the ILSI RSI
workshop was to develop a framework for
assessing children’s health risks from expo-
sure to environmental agents, focusing prin-
cipally on hazard characterization (i.e.,
hazard identification and dose–response
assessment) in the traditional risk assessment
paradigm. Issues related to children’s
exposures have been addressed elsewhere
[e.g., U.S. EPA (U.S. Environmental
Protection Agency) Risk Assessment Forum
(2000)]. In the workshop and in this article,
the term “children” was defined to include
humans from conception through organ
maturation (in adolescence) (see “Risk
Characterization and the Framework” for
further discussion of this definition). It was
recognized that the effects of childhood
exposures may present during childhood or
later in life and that the framework should
incorporate this understanding. Use of a
framework can reveal what already is known
as well as what is not yet known, identifying
critical data gaps and research needs.
The framework for assessing risks to
children from exposure to environmental
agents incorporates many of the principles
and elements of other frameworks and risk
assessment guidance developed by the
U.S. EPA over the past decade (e.g.,
U.S. EPA 1997; U.S. EPA Risk Assessment
Forum 1992). It is responsive to, and consis-
tent with, the directives articulated in the
U.S. EPA Administrator’s policy guidance
(U.S. EPA 1995a) and Executive Order
13045 (Clinton 1997).
The proposed framework, presented in
Figure 1, is broadly analogous to frameworks
previously established by the U.S. EPA for
use in its risk assessment/risk management
process. It must be emphasized repeatedly
that risk assessment is an iterative, not a lin-
ear, process. This concept is rigorously rein-
forced by the graphic inclusion of many
arrows coursing back and forth, up and
down, and around the framework.
The proposed framework retains the three
major steps envisioned in the risk assessment
phase of the risk assessment/risk management
process—problem formulation, analysis, and
risk characterization—refining each to cap-
ture the areas of special emphasis for the life
stages constituting “childhood” (i.e., concep-
tion through adolescence). As with these
other frameworks, the proposed framework
for assessing risks to children from exposure
to environmental agents visualizes its role
within the larger context of an integrated
process. This integrated process is illustrated
in Figure 2. The integrated process presumes
that before any significant effort is made to
conduct a risk assessment, a planning and
scoping exercise has been conducted to assure
an understanding of the purpose(s) for which
the assessment is being done and what its
scope should and/or can be, given available
information. As the 1997 Cumulative Risk
Assessment Guidance (U.S. EPA 1997)
states:
The risk manager must explain clearly why the
assessment is being performed and what questions
need to be addressed. The manager must also
advise the assessors, economists, engineers, and
This article is part of the mini-monograph
“Assessing Risks in Children from Exposure to
Environmental Agents.”
Address correspondence to S. Olin, Risk Science
Institute, International Life Sciences Institute, One
Thomas Circle, Ninth Floor, Washington, DC
20005 USA. Telephone: (202) 659-3306. Fax: (202)
659-3617. E-mail: solin@ilsi.org
This project was conducted under a cooperative
agreement (CR 82730801) with the U.S.
Environmental Protection Agency, Office of
Research and Development, National Center for
Environmental Assessment, Washington, DC.
Financial support is gratefullly acknowledged
from the U.S. EPA (the National Center for
Environmental Assessment/ORD and the Office of
Children’s Health Protection), Health Canada, the
American Chemistry Council, CropLife America,
and the International Life Sciences Institute.
The views expressed by the authors do not neces-
sarily reflect the views and policies of the U.S.
Environmental Protection Agency, the International
Life Sciences Institute, or any of the authors’ affili-
ated organizations, and mention of trade names of
commercial products does not constitute endorse-
ment or recommendation for use. 
The authors delcare they have no competing ﬁnan-
cial interest.
Received 2 January 2003; accepted 8 October 2003.
A Framework for Assessing Risks to Children from Exposure to
Environmental Agents
George Daston,1 Elaine Faustman,2 Gary Ginsberg,3 Penny Fenner-Crisp,4 Stephen Olin,4 Babasaheb Sonawane,5
James Bruckner,6 and William Breslin7
1The Procter & Gamble Company, Cincinnati, Ohio, USA; 2Department of Environmental Health, University of Washington, Seattle,
Washington, USA; 3Connecticut Department of Health, Hartford, Connecticut, USA; 4Risk Science Institute, International Life Sciences
Institute, Washington, DC, USA; 5National Center for Environmental Assessment/Ofﬁce of Research and Development, U.S. Environmental
Protection Agency, Washington, DC, USA; 6College of Pharmacy, University of Georgia, Athens, Georgia, USA; 7Eli Lilly and Company,
Greenﬁeld, Indiana, USA
In recent years there has been an increasing focus in environmental risk assessment on children as
a potentially susceptible population. There also has been growing recognition of the need for a
systematic approach for organizing, evaluating, and incorporating the available data on children’s
susceptibilities in risk assessments. In this article we present a conceptual framework for assessing
risks to children from environmental exposures. The proposed framework builds on the problem
formulation → analysis → risk characterization paradigm, identifying at each phase the questions
and issues of particular importance for characterizing risks to the developing organism (from con-
ception through organ maturation). The framework is presented and discussed from the comple-
mentary perspectives of toxicokinetics and toxicodynamics. Key words: children’s health,
developmental toxicity, framework, life stage, risk assessment, toxicodynamics, toxicokinetics.
Environ Health Perspect 112:238–256 (2004). doi:10.1289/ehp.6182 available via
http://dx.doi.org/ [Online 25 November 2003]
Assessing Risks in Children Mini-Monographother contributing experts on the planning team
of any interested party, affected party, or policy
interests to be considered in the context of the risk
issue. These factors may influence the risk man-
agement options, management goals, key partici-
pants, data sources, selection of assessment end
points, or the schedule for developing the assess-
ment. The manager and assessment planning team
must discuss any regulatory basis for the risk
assessment and what kind of information is
required to satisfy such requirements.
The Guidance goes on to say:
Initially, the risk assessor and manager (and the
planning team) need to evaluate and select the
kind of risk information, exposure scenarios and
assessment issues that need to be covered. At this
point, most EPA assessments focus on technical
information related to the sources, effects, popula-
tions and the routes of exposure. Reasons to limit
the technical scope of the assessment must be
stated explicitly and must include details on limi-
tations on resources, data, the impact of risk ele-
ments on the risk estimate, and methods available.
In cases where an element of risk is likely to be
important, but no valid data are available, the
assessor must highlight this deﬁciency or use judg-
ment or assumed values to approximate the miss-
ing data. Such judgments and approximations
must be noted clearly and explained to the
manager in the risk characterization.
Problem Formulation
The stage is now set to proceed to the first
phase of risk assessment: problem formula-
tion. Problem formulation continues and
expands the characterization of exposure and
effects as well as the examination of the ade-
quacy of scientiﬁc data and data needs, policy
and public health issues, and specific factors
to deﬁne the feasibility, scope, and objectives
for the risk assessment. Problem formulation
provides an early identiﬁcation of key factors
to be considered to develop a scientifically
sound risk assessment. It should include a
statement of the key questions the risk assess-
ment is seeking to answer, with a rationale for
focusing the assessment on particular ages or
toxic effects.
The proposed framework identifies three
dimensions in problem formulation—expo-
sure, host factors, and biological effects—and
emphasizes, by inclusion of arrows pointing in
both directions between the three, the
reciprocal dependence of each dimension upon
the others. Problem formulation is grounded
in a clear articulation and understanding of
several key elements:
• Objective—Deﬁning the purpose of the risk
assessment. Why is it being done? How will
it be used? What is the public health need?
What is (are) the risk question(s) being
asked?
• Overall scope—Determining the scope of
the risk assessment, general or specific. Is
the assessment to consider, for example, all
developmental phases from in utero through
adolescence in the general population and
all possible sources and routes of exposure
(aggregate and cumulative), or is it conﬁned
to speciﬁc scenarios such as children living
near a specific Superfund site potentially
exposed via air, soil, and groundwater?
• Exposure considerations: Preliminary
identification of life stages potentially
affected—Identifying the life stages likely to
be affected, given the properties of the envi-
ronmental agent(s) and the deﬁned scope of
the assessment. Qualitatively characterize
the sources, duration, and pattern of expo-
sures to women of childbearing age and/or
children, as appropriate, including potential
for dietary, drinking water, soil, and air
exposures, pharmaceutical use, and other
sources. Will all ages be at risk for exposure
(e.g., from air toxicants, water contami-
nants), or are we only concerned with pre-
natal exposures, newborns (e.g., from
nursing exposures), or older children (agents
in diet or soil, or pediatric drugs)? This
decision may be site speciﬁc (e.g., only chil-
dren of a certain age are exposed, if it is a
day care center that 3- to 5-year-olds attend)
or it may be less speciﬁc and thus dependent
upon the exposure characteristics of several
different life stages/age groups.
• Biological effects considerations: Preliminary
identiﬁcation of toxic effects and kinetic and
dynamic proﬁles—What do we know about
the chemical being evaluated that may be
important for considering age-speciﬁc risk?
Does the chemical cause known organ-spe-
ciﬁc toxicity? What organs are affected, and
how are these organs potentially differen-
tially susceptible during development? What
should be the specific time periods of con-
cern? Do we know of kinetic or dynamic
considerations that might make the chemical
differentially toxic during development?
• Result of problem formulation—The
outcome of this phase of risk assessment
should be the accumulation of the informa-
tion needed to develop a conceptual model,
shown in the proposed framework as a task
linking the problem formulation phase to
the analysis phase. The conceptual model
can be either a diagram/flow chart or a
written description of the predicted key
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Figure 1. Proposed framework for assessing risks to children from exposure to environmental agents.relationships between the host factors and
the biological effects, informed by the initial
identiﬁcation of exposure scenarios, exposed
life-stage groups, and the identiﬁed charac-
teristics and toxicological end points of
the chemical(s) that may contribute to
children’s risk. 
Analysis
The analysis phase of risk assessment consists
of an in-depth characterization of exposures
and evaluation of the potential health effects
(hazard characterization) on a life stage–spe-
ciﬁc basis. The hazard characterization should
include both hazard identification and
dose–response assessment. The life stages for
which the analysis is to be conducted will
have been identified, at least tentatively, in
the conceptual model. It is important to note
that the proposed framework incorporates the
concepts of timing and dosimetry as unifying
factors for both the exposure assessment and
hazard assessment components of the analysis. 
• Characterization of age-speciﬁc exposures—
Characterize exposures for all life stages of
interest. Are quantitative exposure data
available? Can exposures be estimated? Can
life stages/age groups be ranked by expo-
sure? Which life stages/age groups are most
likely to be exposed more than adults?
• Evaluation of potential for life stage–speciﬁc
health effects—Consider data available for
hazard identification and dose–response
assessments for specific life stages. (Access
information on the capabilities of humans
and animal models in the selected life stages
to absorb, metabolize, and excrete xenobi-
otics and on the timing of developmental
vulnerabilities in terms of organ and systems
growth/maturation.) Evaluate the toxicoki-
netic profile of the chemical to understand
major clearance pathways and mechanisms
for activation and detoxiﬁcation. Evaluate the
toxicodynamic effects of the chemical rang-
ing from cellular/molecular mechanisms of
action to identifying the critical target organs
and types of toxic effects. Consider how each
potentially exposed age group might handle
the chemical in terms of kinetic factors
[Which developmental life stages are likely to
have greater internal dose (per unit of expo-
sure) than adults based upon absorption,
clearance, activation/detoxification?] and
toxicodynamic/vulnerability factors (What
are the critical periods of organ or systems
development that can be affected by the
chemical based upon its mechanism of
action? What are the target organs and toxic
effects of concern?).
• Consider need for further assessment—
Determine the need for continuing with the
assessment based upon the following three
issues: a) unique effects (Are there any life
stage/toxic effect combinations that repre-
sent novel toxicities that would not be seen
in adult-only exposure scenarios?); b) quan-
titative differences in effect (Are there any
developmental life stages in which a greater
effective exposure dose and/or greater
adverse reaction is likely compared with
adults? If so, prioritize for further analysis.);
c) lack of adult risk assessment: if there is no
preexisting or relevant adult risk assessment,
then continue with the children’s analysis.
This may indicate that children’s exposure
issues are unique in this scenario such that
an adult assessment is unnecessary. In mak-
ing this decision, one must remain mindful
of legislative or other mandates that may
direct what is or is not to be done.
• Consider assessment options and their
feasibility and appropriateness for prioritized
life stages—Based upon the public health
needs, data available, and level of quantita-
tive and qualitative assessments possible, an
appropriate level of analysis for the risk char-
acterization will be determined. Metho-
dological options include the following:
a) Qualitative approaches in which the risk
for one or more developmental life stage is
described as an additional uncertainty or
source of intersubject variability in the adult-
based assessment. Although such an
approach may not drive the risk assessment,
it could add weight to its overall conclusions.
b) Semiquantitative approaches in which
uncertainty factors are modiﬁed as needed,
or a speciﬁc children’s uncertainty/safety fac-
tor is considered. c) Quantitative analysis of
exposure differences in which standard expo-
sure equations are modiﬁed to capture chil-
dren’s behaviors and life-stage exposure
variables. d) Quantitative analysis of kinetic
differences, using life stage–speciﬁc physio-
logically based toxicokinetic (PBTK)
approaches, if feasible and appropriate.
e) Quantitative analysis of toxicodynamic
differences based upon dose–response assess-
ment of effects in developmental life stages
relative to adults. f) Quantitative approaches
to describe interchild variability within a
given life-stage group. This analysis phase
can determine that a single approach suf-
ﬁces, or that a combination of two or more
of these options is needed, or that other
approaches are required to address the chil-
dren’s risk questions raised in problem
formulation.
Risk Characterization
The final phase of the risk assessment
process is risk characterization. Risk charac-
terization is the final integrative step of risk
assessment for both ecological and human
health assessment for any life stage. The
U.S. EPA Risk Characterization Policy states
that “risk characterization integrates infor-
mation from the preceding components of
the risk assessment and synthesizes an overall
conclusion about risk that is complete, infor-
mative, and useful for decision makers”
(U.S. EPA 1995b).
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Figure 2. Stages in the integrated risk assessment process (U.S. EPA 1997).Risk characterization employs the methods
selected in the earlier phases to calculate or oth-
erwise assess risks to life-stage groups priori-
tized for detailed analysis. It results in a
statement of the likelihood that children’s risks
for speciﬁc effects will be higher or lower than
adult risks, to what degree these groups may
differ, and how this impacts overall risk con-
clusions regarding the scenarios analyzed.
High-quality risk characterizations also include
analyses of uncertainty and variability and
describe the impact(s) of these two factors on
the integrity and accuracy of the assessment.
• Conduct life stage–specific risk assess-
ment(s)—This step is the natural culmina-
tion of the preceding phases and could
range in level of complexity from a straight-
forward justification for use of a particular
uncertainty factor to a highly reﬁned quan-
titative analysis incorporating mode of
action, dose–response analysis, and child-
specific toxicokinetic and toxicodynamic
data. 
• Characterize risks for children—Develop
narrative description of the overall process
of consideration of potential risks for chil-
dren and the conclusions from the risk
assessment, including characterization of
variabilities and uncertainties and identiﬁca-
tion of critical assumptions, confidence in
the database, data gaps, and research needs.
This would also include a discussion of
comparative risks for children versus adults.
Toxicokinetic Considerations 
in Understanding Children’s
Health Risks from Exposure 
to Environmental Agents
We now consider how an analysis of toxico-
kinetics could be conducted within the pro-
posed framework, including the types of data
and considerations that would be needed at
each step in the process. The goal is not to
provide detailed instructions or guidelines for
how the toxicokinetic analysis should be con-
ducted. Instead, the focus is on creating a
broad perspective that ensures that the rele-
vant questions related to absorption, distribu-
tion, metabolism, and excretion (ADME) of
xenobiotics across the various developmental
stages (in utero through adolescence) are
addressed.
The approach taken in a risk assessment is
influenced by the type of data available. In
some cases, assessment of children’s risks by
extrapolation from animal data for in utero or
juvenile life stages may be possible.
Alternatively (or perhaps additionally), the
database may permit an extrapolation from
human adults to early life stages. Although
the latter type of extrapolation is the primary
focus of this toxicokinetic discussion, much of
what is discussed and recommended is also
relevant to direct extrapolation from animal
toxicity studies.
Our overall approach is to a) identify the
key toxicokinetic determinants that tend to
govern internal dose in general; b) summarize
what is known regarding these determinants
for the in utero period and for children;
c) describe how this information can be used
to better refine internal dose estimates for
these early life stages; d) discuss how the toxi-
cokinetic approaches and methods fit into
the overall children’s risk assessment frame-
work; and e) identify critical data needs.
Toxicokinetics is addressed primarily in the
problem formulation and analysis phases,
providing input to risk characterization. 
Problem Formulation for the
Toxicokinetic Analysis
Problem formulation begins with a statement
of the purpose of the assessment, followed by
definition of the problem/issue being
addressed and identification of potential
methods and data sets that may be applied.
First, the broad goal of toxicokinetic
assessment is to improve the characterization
of risks by developing more accurate internal
dose estimates for specific life stages and
between genders, species, dose routes, and
exposure patterns. Toxicokinetic assessment
can remove some of the uncertainty in risk
assessment by replacing interspecies scaling
defaults with more precise estimates of inter-
nal dose. This allows the internal dose associ-
ated with toxicity in experimental animals to
be related to the internal dose humans may
experience via environmental exposures under
various conditions of exposure. Further,
toxicokinetic assessments can take into
account the range of interindividual variabil-
ity (where such distributions have been
described) to show both the central tendency
and upper-bound estimates of internal dose.
Toxicokinetic assessments also can illuminate
the mechanism of toxicity by providing vari-
ous estimates of internal dose whose relation-
ships to adverse effect can be tested with
regression or other correlational analyses.
Those dose metrics (e.g., metabolites vs. par-
ent compound) best correlated to toxicity are
also most likely to be related to the toxic
mechanism. These functions are equally rele-
vant to risk assessments involving the in utero
and postnatal periods.
Each toxicokinetic assessment needs to
consider the speciﬁc objectives for the risk sce-
nario being analyzed. This involves an under-
standing of scenario-speciﬁc factors that affect
exposure and chemical-speciﬁc toxicodynamic
factors that affect target organ and key internal
dose metric(s) (e.g., parent compound vs.
metabolite). Problem formulation also needs
to take stock of the key toxicokinetic factors
that generally tend to govern internal dose,
identify the types of chemical-specific and
developmental data needed for a children’s
toxicokinetic analysis, then develop a set of
analytic options for conducting the analysis.
These aspects of problem formulation are
summarized brieﬂy below.
Exposure inputs to toxicokinetic analysis.
Exposure assessment is a particularly critical
input to children’s toxicokinetic analysis,
given that per body weight, children’s expo-
sure patterns and rates often differ con-
siderably from those of adults. Problem
formulation identiﬁes the most likely route(s)
of uptake (gastrointestinal absorption, dermal
penetration, respiratory tract absorption),
assesses whether first-pass effects will occur
(e.g., hepatic extraction before systemic circu-
lation) after oral exposure, and considers
which contact sites will receive the largest
applied dose. It also considers how dose rate
will be affected by exposure scenario, whether
sporadic (e.g., soil ingestion) or continuous
(e.g., inhalation), and whether occurring as a
single bolus (e.g., pica ingestion) or more
evenly spread out (e.g., contaminants in
drinking water or diet). The behaviors and
physiologic factors that lead to greater expo-
sures during childhood were recently summa-
rized (U.S. EPA Risk Assessment Forum
2000).
The following factors need to be extracted
from exposure assessment for input to toxico-
kinetic analysis for children: a) ages at which
exposure occurs and behaviors that lead to
exposure; b) route(s) of exposure; c)c hemical
form of contaminant in exposure medium and
estimates of bioavailability; d) pattern of expo-
sure (intensity—how much inhaled, ingested,
contacted per event; frequency—how often;
duration—over how many days, weeks, or
years); e) estimate of daily dose (external expo-
sure dose), which also considers body weight,
breathing rate during rest and play activities,
etc. Information should be sought on distribu-
tions of exposure across children’s age groups
to prioritize age groups for further analysis and
to prepare for a toxicokinetic analysis that can
represent the range of exposures and internal
doses considered possible.
Toxicodynamic factors to consider in
toxicokinetic analysis. Toxicodynamics and
mechanism of toxicant action have a direct
bearing on how the toxicokinetic analysis will
be framed. Problem formulation should eval-
uate target organ speciﬁcity to determine the
compartments for which estimates of internal
dose will be needed. This is also affected by
mechanism of action considerations, which
may show that metabolic activation at one
site leads to toxicity in another. The mecha-
nism of action also can determine which dose
metric(s) need to be evaluated, both in terms
of parent compound versus metabolites and
in terms of peak versus area under the curve
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PBTK model development. During the analy-
sis phase, this information needs to be com-
bined with knowledge about children’s
functional capacity in these critical pathways
to derive internal dose estimates specific to
children.
Generally important toxicokinetic
determinants. Regardless of whether animals
or humans (adults or children) are being
modeled, certain toxicokinetic inputs are
likely to be more influential than others in
determining internal dose. Recognition of
this early in the process ensures that the ana-
lyst will prioritize these inputs for special
attention and thus decrease uncertainties (to
the extent possible) in the areas most likely to
drive the assessment. However, the goal of
problem formulation is not to eliminate any
toxicokinetic factors from consideration; for
certain chemicals or age groups, additional
factors may take on a more prominent role.
The importance of such additional factors
may only come to light after an initial analysis
and may be part of an iterative process.
Key factors for which data should be
sought include absorption rate for the rele-
vant exposure pathways, distributional factors
(chemical residence at contact site vs. systemic
distribution), blood flow to liver and other
metabolizing or target organs (Kedderis
1997), size of storage compartments such as
fat or muscle, availability of plasma protein
binding sites and maternal, placental, and
embryo/fetal factors for the analysis of
in utero exposure, metabolism rates for both
activation and detoxiﬁcation pathways at the
various life stages in which exposure occurs,
and ability to eliminate xenobiotics or their
metabolites via renal or biliary clearance or via
pulmonary gas exchange. In each of these
areas, chemical-specific data are needed to
identify the main pathways of chemical acti-
vation, detoxiﬁcation, and clearance as seen in
adults or animal models, and then age-speciﬁc
data are needed to adjust these factors for the
in utero or childhood period.
Listing of analytic options. The toxico-
kinetic assessment could proceed along differ-
ent tracks depending upon the level of
quantitative detail necessary and feasible.
These options range from a completely quali-
tative description of the issues and uncertain-
ties in children’s toxicokinetics to a fully
quantitative analysis involving PBTK model-
ing and Monte Carlo analysis. Problem for-
mulation should evaluate whether the types of
data for these analyses are available for the par-
ticular chemical and life stages being analyzed.
Analysis of Toxicokinetic Data
This phase of the toxicokinetic assessment
reviews the chemical-specific toxicodynamic
and toxicokinetic information described above,
together with the child/age group-specific
toxicokinetic information. The major ques-
tions raised in this phase are a) How does toxi-
cokinetics affect the toxic mechanism of the
chemical via activation or detoxiﬁcation path-
ways? b) What are the key dose metrics and
target organs for the chemical being analyzed?
c) What are the major in utero or child-speciﬁc
toxicokinetic factors that may alter chemical
fate? d) Based upon internal dose considera-
tions, which age groups should be prioritized
for more detailed analysis? e) Which toxico-
kinetic analytical methods are best suited to
evaluating children’s internal dose? f) Once the
analysis is conducted, what do the results tell
us about how internal exposure can vary (per
unit external dose) across developmental stages
and between children and adults? The stepwise
process outlined below is intended to address
these questions.
Analysis of chemical-specific data. The
first task is to combine toxicodynamic and
toxicokinetic information from animal mod-
els and, to the extent available, from adult
humans; this type of data will usually be lack-
ing in children or juvenile animals. The com-
bination of toxicodynamic and toxicokinetic
data is used to understand the toxicokinetic
determinants of toxicity— whether metabo-
lism represents detoxiﬁcation or activation or
both. This involves identification of the
various enzymes that may be important in
chemical activation and removal (e.g., phase I
enzymes—speciﬁc cytochrome P-450s (CYPs),
peroxidases, dehydrogenases; phase II sys-
tems—glucuronidation, sulfation, glutathione
conjugation; other enzymes—epoxide hydro-
lase, serum esterases). Because an enzyme can
be part of an activation pathway for one
chemical and yet be detoxifying for another
[e.g., glutathione S-transferases (GSTs), epox-
ide hydrolase, various CYPs], determining the
role of a given enzyme is highly chemical spe-
ciﬁc. Therefore, the toxicological signiﬁcance
of the presence or absence of an enzyme at a
particular developmental stage is also chemical
speciﬁc.
Known or anticipated target organs for the
chemical should be identified, and the key
activation and detoxiﬁcation steps in each tar-
get organ should be evaluated. Internal dose
metrics for the active form of the chemical can
be selected for each target organ. Because tar-
get sites can be different in the fetus or child
from those in adults, toxicity information for
early life stages is particularly important,
when available.
Other toxicokinetic determinants of
chemical fate should be evaluated so the
mechanisms and factors involved in chemical
absorption (from scenario-relevant portals of
entry), distribution (e.g., serum binding, par-
titioning), and excretion (e.g., renal, biliary,
exhalation) are understood.
This segment of the analysis phase should
provide the following chemical-speciﬁc infor-
mation: identiﬁcation of key metabolic path-
ways for activation and detoxiﬁcation; target
organs for which dosimetry information would
be needed; key dose metrics that should be
modeled or evaluated in other ways; toxicoki-
netic factors that control chemical distribution
and excretion. 
Analysis of age group–speciﬁc toxicokinetic
factors. Numerous toxicokinetic factors differ
across life stages, particularly because of
rapidly changing physiology and the immatu-
rity of various systems in utero and in early
life. However, the importance of any single
factor in altering internal dosimetry depends
upon the toxicokinetic mechanisms involved
in the ADME of the chemical, the life stage
where exposure occurs, and the interplay of
other factors that may tend to accentuate or
offset the dosimetry change. For example,
immature metabolism in early life via phase I
enzymes may have less influence on internal
dose and long-term retention of highly lipid-
soluble organochlorines whose toxicokinetics
is most inﬂuenced by partitioning into lipids.
An example of offsetting factors would be
where immaturity of metabolism causes both
the activation and detoxification steps to be
slow relative to those of older age groups. In
this case, formation of toxic metabolites may
be low, but their removal may be sufﬁciently
impeded (perhaps also by slow renal and bil-
iary clearance) to create similar or higher levels
of ultimate toxicant at key target sites.
These considerations illustrate the need
for this phase of the analysis to take into
account the various ADME differences possi-
ble in early life. The following general discus-
sion provides a framework into which
chemical-speciﬁc information can be added to
focus the toxicokinetic analysis for children.
Absorption factors. The exposure
scenario (age groups involved, contaminated
media, behaviors leading to exposure) will
determine the route of uptake: oral, dermal,
inhalation, or a combination of several routes.
Also, as stated above, the scenario will dictate
the frequency and intensity of exposure,
which can differ substantially across age
groups. Aside from differences in exposure,
the amount of uptake can differ because the
percent absorption from the gastrointestinal
(GI) tract, respiratory tract, and skin may be
different in newborns and infants relative to
older children and adults.
Oral absorption. Greater oral absorption of
lead (Pb) has been documented in infants rela-
tive to adults and attributed to greater
pinocytic activity of intestinal epithelium prior
to closure. This nonselective uptake mecha-
nism may also increase the absorption of other
metals and organic compounds, as suggested
by data in juvenile rats [Kostial et al. 1978;
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rodents, closure occurs around the time of
weaning.
A variety of other factors may influence
oral absorption in different age groups, includ-
ing nutrient deﬁciencies (e.g., low iron or cal-
cium intake increases the absorption of lead;
low stomach pH up to 2 years of age; blood
flow and surface area of GI tract absorptive
regions; presence of milk in stomach)
(NRC 1993). 
The possibility of higher GI uptake of
ingested chemicals early in life should be eval-
uated within the context of behavior of the
chemical in the gut. If it is generally well
absorbed in rodents and adult humans by the
oral route (e.g., small organic molecules),
then any increase in absorption during early
life stages may not create a large difference in
uptake. However, for poorly absorbed chemi-
cals (e.g., a variety of metals), increased
uptake in children may be an important fac-
tor in the exposure and risk assessment. For
such chemicals, the mode of absorption
should be investigated to determine whether
these mechanisms may be enhanced in early
life. Further, GI uptake data for this and anal-
ogous chemicals in children or juvenile ani-
mals should be sought. These efforts may
allow age group-speciﬁc adjustment factors to
be applied for GI absorption.
Respiratory dosimetry and absorption.
PARTICLES AND AEROSOLS. Inhalation exposure
during early life may lead to a different degree
of exposure than at older ages because of the
greater respiratory volume per surface area in
young children. On average this can lead to an
approximately 2 fold increase in respiratory
tract exposure (per unit surface area) of young
children compared with adults (NRC 1993;
U.S. EPA 1999, 2000). Preliminary modeling
efforts for young children suggest that this dif-
ferential can be larger when considering local
deposition (Martonen et al. 2000). This expo-
sure dose differential for particles and aerosols
may be of particular consequence to young
children who are sensitive to respiratory irri-
tants and allergens because of asthma or other
conditions. Further, in asthma the changes in
breathing pattern and respiratory volume/resis-
tance may create local exposure patterns differ-
ent from those in healthy children or adults.
Therefore, it is important to analyze respira-
tory deposition of particles and aerosols in
children, both healthy and asthmatic. This can
be aided by the development of regional
deposited dose ratio (RDDR) models that take
into account respiratory physiology at differ-
ent life stages as well as a distribution of parti-
cle sizes. These models would be similar to
those currently used in extrapolating from ani-
mal-to-human data for inhalation reference
concentration (RfC) development (U.S. EPA
1994). Additional consideration should be
given to whether there are life stages where
mucociliary clearance and macrophage clear-
ance of particles are substantially different
from those of adults. Until these models are
available, the greater inhalation volume per
respiratory surface area in young children
should be considered for input into the
analysis. 
REACTIVE GASES. RfC methodology uses
the regional gas dose ratio (RGDR) to
extrapolate from extrathoracic dose in animals
(where the toxicity data are obtained) to adult
humans. This adjustment factor is based
upon the difference in respiratory volume per
surface area in the upper respiratory tract
across species. This methodology can be
extended to children of various ages by use of
upper respiratory tract surface area and
inhalation volumes for these ages. Lacking
RGDR data, the overall approximately 2-fold
differential in inhalation volume per respira-
tory surface area described above may be
assumed as a ﬁrst approximation for reactive
gases. 
NONREACTIVE GASES. Uptake of this class
of inhaled chemicals is currently modeled by
estimating the difference in pulmonary
absorption (net systemic uptake) between test
animals and adult humans. Uptake across
alveoli is driven by the blood:air partition
coefficient, respiratory rate, cardiac output,
and systemic extraction (e.g., partitioning
into lipid, removal from circulation via
metabolism or excretion). However, for
chemicals that rapidly reach steady state (e.g.,
perchloroethylene), the major (but not only)
determinant of net uptake is the partition
coefﬁcient. In this case, increased respiration
and cardiac output also lead to increased
exhalation. This may be especially relevant for
neonates and infants whose metabolic and
renal capacities are immature and quite lim-
ited. The blood:air coefficient is affected by
the presence of carriers (e.g., hemoglobin) or
lipid in blood, which can vary across species
and age groups. It may be possible to develop
a database of children’s partition coefﬁcients
(across age and chemicals) based on partition
coefﬁcients determined in vitro and to model
uptake of these gases in children based upon
data sets in adult animals and humans.
Dermal absorption. For toxicokinetic
assessment of dermal absorption, a major con-
sideration is whether dermal contact with the
contaminated medium is greater in children
of certain ages than adults because of behav-
ioral factors (e.g., crawling; play activities
leading to high percentage of the body
becoming covered with soil) or physiological
factors (higher skin surface area per body
weight in young children) (NRC 1993). A
second consideration is whether children’s
skin is more permeable to chemicals than the
skin used to derive uptake factors, typically
adult animal or human skin. As full-term
newborns have a well-developed stratum
corneum, it is generally believed that the age
of the child has little bearing on dermal per-
meability (U.S. EPA 1992). This has been
shown in limited in vitro testing using skin
from neonates and adults (U.S. EPA 1992;
Wester et al. 1985). However, the skin of pre-
mature neonates can be substantially more
permeable than that of full-term neonates
because of immaturity of the stratum
corneum (Barker et al. 1987; U.S. EPA
1992). This potential for increased dermal
uptake in premature neonates may be an
important factor in scenarios where these
neonates are dermally exposed to contami-
nants present in bath water or to chemicals in
hygienic or diaper-rash products. Dermal
penetrability may also be enhanced when skin
is damaged or highly hydrated (U.S. EPA
1992). These conditions are more prevalent
in infants whose skin under a diaper is more
likely to be excessively hydrated and possibly
compromised by irritation and rash.
A ﬁnal consideration is whether chemical
sorption on the exposure matrix (e.g., soil)
significantly impedes dermal penetration.
Although this factor affects adults as well as
children, in certain cases binding to the expo-
sure matrix may substantially decrease dermal
uptake and thus reduce the importance of
any child/adult differences in this route
of exposure.
Distribution factors. Distribution into
systemic compartments depends upon a num-
ber of chemical-speciﬁc factors: lipid and water
solubility, as these determine partition coefﬁ-
cients; chemical size; ability to be carried by
transporters across membranes, and afﬁnity for
plasma or tissue proteins. Age group–speciﬁc
factors that affect chemical disposition include
lipid and water content of the body (generally
more water and less lipid in neonates), quantity
of plasma protein binding sites (fewer in
neonates; those that do exist may be less avail-
able for xenobiotic binding than at older ages),
and more permeable blood–brain barrier in
neonates. These factors tend to increase the
volume of distribution for many chemicals in
early life (Ginsberg et al. 2002, 2004). Higher
volume of distribution can lead to lower blood
concentrations and longer chemical half-lives,
as the chemical is less available to the central
compartment for transfer to sites of metabo-
lism (e.g., liver) and elimination (kidney, lung,
bile). However, the interplay of distributional,
metabolic, and elimination factors can be com-
plex, thus defying use of a simple adjustment
factor to compensate for differences in chemi-
cal distribution in children. PBTK modeling
for children holds the greatest potential to
combine the absorption factors described
above with distribution, metabolism, and elim-
ination information to enable predictions of
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time. Short of this approach, there are some
simplified generalizations regarding distribu-
tion and age groups that may be useful in the
assessment: greater permeability of the
blood–brain barrier in early life can produce
higher chemical concentrations in the central
nervous system (CNS) of children; lower lipid
content in early life would cause less storage
and retention of lipophilic chemicals; less
plasma protein binding in early life might
accentuate chemical toxicity because of a
greater percentage of free chemical in the circu-
lation (as suggested for lidocaine, cisplatin and
other drugs; Kakiuchi et al. 1999; Zemlickis
et al. 1994 ). The importance of such distribu-
tional differences across age groups may be
described qualitatively for the chemical under
assessment. However, PBTK modeling would
be needed to quantitatively incorporate
such factors.
Two additional distributional phenomena
critical to early life exposures are placental
transport of chemicals from mother to fetus,
and partitioning of chemicals from maternal
blood into breast milk. The existing database
suggests that most chemicals can cross the
placenta, although the rates can vary depend-
ing upon molecular size, lipophilicity, and
serum protein binding (Ginsberg et al. 2002,
2004). This suggests that toxicant exposure in
the mother will generally lead to toxicant
exposure of the fetus, although maternal
metabolism/clearance factors may lead to
lower concentrations in the fetus compared
with the mother. Thus, fetal exposure needs
to be considered where maternal exposure
occurs. Fortunately, there are PBTK models
that describe pregnancy and fetal exposure
(Clewell et al. 1999; Krishnan and Andersen
1998). Similarly, the partitioning of chemi-
cals into breast milk has been evaluated for
various types of chemicals and can be
described via modeling approaches in the
absence of empirical data (Byczkowski et al.
1994).
Metabolism factors. A companion article
(Ginsberg et al. 2004) in this mini-mono-
graph summarizes a variety of in vitro data
(enzyme levels and function) and in vivo data
(therapeutic drug pharmacokinetic studies)
that show that young children, particularly in
the ﬁrst 2 months of life, are immature with
respect to metabolic and renal clearance. This
appears to be a consistent finding across a
number of metabolic pathways including a
variety of CYPs (including CYP1A2 and
CYP2E1, two that are particularly important
in toxicant activation), glucuronidation, serum
esterases, epoxide hydrolase, and perhaps also
GSTs. There are fetal forms of some enzymes
(e.g., CYP3A7, GST-pi), but these appear to
have a different range of speciﬁcities from the
adult forms. Renal function is also immature
in the ﬁrst weeks to months of life, leading to
prolonged half-life of a variety of renally
cleared drugs. This condition changes by
6 months of age, and for a time, some enzy-
matic functions (most notably CYP1A2)
appear to become somewhat more active than
in adults (Dorne et al. 2001; Ginsberg et al.
2002, 2004; Renwick et al. 2000). This may
be a function of the higher liver mass per body
weight (and assumed higher hepatic blood
ﬂow per body weight) that exists in children
compared with adults. This becomes normal-
ized when scaling across ages on a surface area
rather than body weight basis (Gibbs et al.
1997), which suggests that beyond 6 months
of age a surface area correction may be a good
first approximation of how metabolism
changes with age once a system has reached
functional maturity (~6 months–1 year for
many systems).
The significance of these changes in
metabolism with postnatal development
depends upon whether chemical metabolism
leads to activation or detoxification, which
pathways are involved in activation and
detoxiﬁcation, and whether blood ﬂow limita-
tions to the metabolizing tissue (e.g., the
liver) prevent the full expression of changes in
enzymatic function (Kedderis 1997). The
importance of changes in metabolic function
also depends upon whether other clearance
pathways (e.g., renal, biliary, exhalation) can
compensate for slow metabolism in early life.
The interplay of distributional, metabolic,
and renal factors is best understood and quan-
titatively evaluated via PBTK models.
However, if these models do not exist and
cannot be developed within the scope of the
children’s risk assessment being performed,
then some simplifying ﬁrst approximations of
chemical clearance and metabolic activation
may be possible from the existing literature.
In vitro and in vivo data sets that are available
provide quantitative data on metabolic pro-
cessing in children relative to adults for a wide
variety of pathways and drugs (Ginsberg et al.
2002, 2004; Hines and McCarver 2002;
McCarver and Hines 2002; Renwick et al.
2000). At a minimum, the slower clearance of
many chemicals very early in life should be
qualitatively discussed in terms of internal
dosimetry and risk implications for children
(e.g., more of parent compound but less of
metabolites present in tissues; also possibly
slower removal of metabolites). It should be
noted that neonate/adult differences in half-
life can be large relative to the default assump-
tions for interindividual pharmacokinetic
variability (3.16 factor), especially when con-
sidering the full range of results from individ-
ual neonates (Ginsberg et al. 2002). This may
warrant semiquantitative approaches such as
adjusting uncertainty factors to incorporate
pharmacokinetics into risk assessments for
newborns. However, this will take careful con-
sideration of chemical mechanism of action
(activation and detoxification pathways) and
potential blood ﬂow limitations. Ultimately, a
PBTK model would provide the best assur-
ance that all relevant pharmacokinetic factors
have been accounted for when estimating
internal doses.
In utero, placental, fetal, and maternal
factors can all play a role in chemical metabo-
lism. A variety of placental enzymes exist and
can be induced by maternal exposure to ciga-
rette smoke and other types of drugs and toxi-
cants (Juchau 1980). Metabolism by the fetus
itself can in some cases outweigh the impor-
tance of maternal metabolism in terms of fetal
toxicant exposure. This has been seen with
fetal mice, whose risk of lung tumors from
maternal exposure to 3-methylcholanthrene
was greatest when the fetal mice had induced
levels of CYP1A1 and the mother was nonin-
ducible (Anderson et al. 1989; Miller et al.
1990). Lower tumor incidence was seen in off-
spring when the mothers were inducible,
demonstrating the protective role maternal
metabolism can have, even when that metabo-
lism leads to more toxic moieties. Another
issue is that fetal metabolism may create
metabolites less able than parent compound to
cross the placenta back to the maternal circu-
lation [e.g., zidovudine (Garland et al. 1998);
hormonal agents (Slikker et al. 1982)]. This
could lead to an accumulation of metabolites
in fetal tissues. However, the fetus may have
lower exposure to reactive metabolites because
of the lack of activating metabolic pathways,
as is recognized for CYP2E1 in the fetus
(Cresteil 1998).
Understanding the time course for the
development of in utero metabolic capabilities
can identify gestational periods important for
toxicokinetic assessment of placental or fetal
activation. These placental and fetal metabo-
lism factors are best incorporated into a model-
ing framework to be useful in risk calculations.
Elimination factors. As mentioned above,
renal elimination of drugs is generally reduced
in newborns, which is consistent with devel-
opmental studies on the maturation of renal
glomerular filtration and tubular secretory
functions. Biliary excretion can also be dimin-
ished in newborns because glucuronidation
capability and other hepatic functions are
immature in the first months of life.
However, enterohepatic circulation is func-
tional in early life, which can lead to substan-
tial reabsorption of chemicals excreted in bile
(Suchy et al. 1987). Exhalation of volatile
chemicals may be enhanced in the young
because of high ventilation rates per body
weight and the fact that other clearance path-
ways are immature. Although PBTK model-
ing of these elimination pathways in
conjunction with other toxicokinetic inputs
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assume that elimination via renal and biliary
systems will be slower in newborns than in
adults. This can lead to potentially greater
levels of parent compound or metabolites in
newborns, depending upon their primary
route of clearance. The children’s risk assess-
ment should consider the implications of
deficits in chemical elimination during this
early life stage.
Selection of age groups for special focus.
Review of chemical-specific and age
group–speciﬁc data may reveal a speciﬁc age
group of particular concern from a toxico-
kinetic perspective. These would be age
groups where the toxicokinetic mechanisms
central to absorption, distribution, activation,
detoxiﬁcation, and elimination of the chemi-
cal are expected to be most different from
those of adults. In general, as outlined in the
preceding sections, neonates (both premature
and full term) through the first several
months of life are most different from older
age groups and adults. Therefore, this age
period should be carefully considered for the
possibility of substantive changes in internal
dose relative to adults. Somewhat older age
groups (6 months to 2 years) are also impor-
tant from a toxicokinetic perspective in that
these groups generally have greater hepatic
extraction and shorter chemical half-lives
because of larger liver size per body weight
(Gibbs et al. 1997; Ginsberg et al. 2002,
2004). In utero may also be a critical life stage
from a toxicokinetic perspective, as most
chemicals cross the placenta and placental or
in utero enzymes may be sites of chemical
metabolic activation. The other portions of
the risk assessment (exposure assessment; toxi-
city assessment) may identify key life stages
that need to be fully analyzed, regardless of
whether unique toxicokinetic considerations
exist in those stages.
Changes in toxicokinetic function may be
deﬁned within speciﬁc age groupings as a way
to compile and organize the data. It appears
that rapid maturational changes that occur
within the ﬁrst weeks and months of life war-
rant subdividing that period into several age
groups. Beyond that age, broader age group-
ings are possible, given that changes in
metabolism and other factors may be possible
to scale allometrically based upon body sur-
face area. Alternatively, for these age groups a
continuous physiological model based upon a
set of equations that describe physiological
development of organ systems and blood
flows may be suitable (Pelekis et al. 2001).
The risk assessment may dictate that certain
age groups be the prime focus on the basis of
exposure issues or toxicodynamic issues. The
toxicokinetic portion of the analysis can
accommodate this focus, providing some idea
of how internal dose may be affected by the
stage of development during these critical
exposure or susceptibility periods. However,
the risk assessment should also take on as a
focus those age groups that appear to have the
unique toxicokinetic features relative to adults
(particularly the ﬁrst weeks and months of life
as described above).
Selection of analytical approach. The
possible approaches for assessing toxicokinetic
factors as part of a children’s risk assessment
are PBTK modeling, semiquantitative assess-
ment of children’s internal exposure relative to
adults, and qualitative description of the issues
and uncertainties. Each approach has advan-
tages and disadvantages, as described below.
Quantitative approaches: PBTK models.
PBTK models have had great utility in reﬁn-
ing risk assessments involving extrapolation of
exposure and toxicity across species. The same
will likely be true of PBTK modeling for chil-
dren. However, models do not currently exist
that take into account the numerous factors
that can create toxicokinetic differences
between children and adults or that are cali-
brated against actual toxicokinetic data in chil-
dren. Several initial efforts (Gentry et al. 2002;
Haddad et al. 1999; Pelekis et al. 2001) form
useful building blocks, and we can expect chil-
dren’s PBTK models to evolve over the next
few years. Therefore, although this analytical
tool holds great promise for providing reﬁned
estimates of internal dose in children, it has
the drawback of requiring a period of intensive
model development. Other drawbacks include
the fact that PBTK modeling requires a large
amount of empirical data for model calibra-
tion and validation, and these types of data are
not available for environmental toxicants in
children. Therefore, such modeling will be dif-
ﬁcult to validate and will often depend upon
developing conﬁdence in the model structure
by simulating pharmacokinetic data in chil-
dren who have been exposed to therapeutic
drugs. While this will introduce uncertainties,
it does not invalidate this approach.
The combination of PBTK models with
Monte Carlo approaches is potentially quite
useful, incorporating the distribution of chil-
dren’s capacities in the various ADME areas.
In this way, variability within a given age
group of children can be explicitly examined,
and predetermined percentiles of the distribu-
tion of internal dose (e.g., 50th or 90th per-
centile) can be selected for inclusion in risk
calculations. Alternatively, the full distribution
can be used in combination with distributions
for other risk inputs (exposure, dose response)
for a complete probabilistic description of risk.
In this way, the toxicokinetic contribution to
variability and uncertainty in the assessment
can be explicit and readily expressed.
Although PBTK efforts are recommended
for children’s risk assessments, not all types of
assessments may warrant this level of effort,
even when working children’s models are
available. For example, risk assessments in
which the exposure or dose–response inputs
are associated with a high degree of uncer-
tainty may not warrant extensive effort to
refine the toxicokinetic component. In such
cases, screening-level analyses may be the only
realistic option. Additionally, in cases where
toxicokinetic properties of the chemical have
not been well studied in rodents and adult
humans, children’s models become more
uncertain and less worthwhile. Therefore, the
choice of whether to utilize PBTK approaches
for children depends upon whether refined
estimates of internal dose are feasible for chil-
dren and worthwhile relative to the level of
analysis being conducted in other portions of
the risk assessment. 
Semiquantitative approaches. When there
is no need to conduct a detailed quantitative
analysis or when such an analysis is not feasi-
ble, the analyst can consider a semiquantitative
approach. In these cases, review of the under-
lying chemical-speciﬁc and age group–speciﬁc
databases may suggest a potentially greater
internal dose at certain early life stages than in
adult humans or in the laboratory animals
from which toxicity data are extrapolated. For
example, if the chemical could be metaboli-
cally activated to toxic metabolites by
CYP3A7 [e.g., aﬂatoxin B1; 2-amino-3-imida-
zoquinoline (Hashimoto et al. 1995; Kitada
et al. 1989)], a form of CYP prevalent in utero
and just after birth, this may constitute a sufﬁ-
cient rationale to develop at least a semiquan-
titative or screening-level estimate of relative
internal dose in this age group. This would be
the case especially if the active metabolite
formed from CYP3A7 metabolism is expected
to be poorly detoxiﬁed and excreted in this age
group. This screening-level approach can be
seen as supplementing the existing set of
uncertainty factors that already exist in non-
cancer risk assessment, speciﬁcally the half-log
(3.16-fold) uncertainty factor for interindivid-
ual variability in toxicokinetics (Renwick
1998). Although that uncertainty factor is
designed to address a large array of general
interindividual differences that might affect
toxicokinetic handling of xenobiotics (e.g.,
genetics, gender, disease states, other concomi-
tant exposures, age), it may not always be ade-
quate to address specific differences between
subgroups of the population (e.g., children of
certain age groups). The semiquantitative
assessment could evaluate whether a sufﬁcient
difference between children and adults might
exist in the direction of increased toxicant dose
to warrant an age group–specific adjustment
factor for toxicokinetics.
Because this would not be a comprehensive
PBTK approach, the semiquantitative assess-
ment would focus upon one or several key
toxicokinetic factors/pathways. An assessment
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influence the estimate of internal dose has
the disadvantage of greater analytic uncer-
tainty. However, by taking stock of key fac-
tors with obvious implications for internal
dose differences in children, the analysis can
point out what types of concerns exist, how
large the across-age differences may generally
be, and whether more detailed PBTK assess-
ment is ultimately needed to refine the dose
estimate.
The semiquantitative assessment can
evaluate how known differences in key
toxicokinetic pathways (Ginsberg et al. 2002,
2004) may affect the absorption, metabo-
lism, and elimination of the chemical under
analysis. The analysis would be semiquantita-
tive and comparative in that the size of func-
tional differences between children and
adults (e.g., child/adult ratio) would be used
as an initial estimate of the change in internal
dose in a particular age group. Other toxico-
kinetic factors may increase or decrease the
influence of changes in, for example, a spe-
ciﬁc CYP pathway (e.g., differences in blood
flow, protein binding, distribution to CNS,
renal elimination changes, phase II conjuga-
tion activity). These factors would need to be
considered for their possibility to alter or
negate the importance of the key child/adult
difference upon which the analysis is focused.
It is essential that this screening level
approach be described as providing only a
crude estimate of the differences in internal
dose that may be possible, and that the
various uncertainties be made explicit.
Qualitative approaches. When the
review of chemical-specific and age
group–specific toxicokinetic data suggests
that child/adult differences may not cause
substantially higher internal dose in chil-
dren, or where this review indicates large
areas of uncertainty, a purely qualitative
approach may be adequate. This approach
can summarize what is known about the
toxicokinetic properties of the chemical vis-
à-vis the development of toxicokinetic func-
tions in utero and in children. This can lead
to a discussion of how these various factors
may interact to alter internal dosimetry rela-
tive to adults and if there are age groups
where such alterations are more likely. If this
is a considerable source of uncertainty, it
may affect how much confidence is placed
on the overall risk assessment regarding
in utero and children’s exposures.
Engaging the Framework: Addressing
Modeling and Data Needs
The toxicokinetic assessment framework
described above involves a large array of
parameters that need to be informed by
empirical data for a variety of age groups.
Given that there are very few toxicokinetic
data for environmental chemicals in
children, a large number of data gaps will
need to be filled for individual chemicals,
either through new data acquisition (e.g.,
studies in juvenile animals) or by reliance on
surrogate chemicals (e.g., drugs that have
similar metabolism/clearance pathways and
have been tested in children).
To engage the framework there is an
urgent need for the development of well-cal-
ibrated, and to the extent possible, validated
PBTK models for children. These models
can be extensions of adult models with
appropriate adjustments for the physiologic
and metabolism/elimination differences that
exist for children at specific developmental
periods. This modeling can progress in
stages from initial descriptions of children’s
growth and maturation (changes in body
weight and water/lipid composition, body
compartment sizes, tissue blood ﬂows, venti-
lation rates, and serum protein binding
capacity) to more complete, chemical-
specific PBTK models with age-specific
activity data for the major metabolism and
elimination pathways of the chemical.
Model development would likely involve a
number of case studies for speciﬁc chemicals,
which would then lead to a flexible model-
ing framework that would describe the
underlying physiology of children’s develop-
ment and be adaptable to a variety of chemi-
cals and age groups. A similar approach can
be used for the in utero period, in which
established models for speciﬁc chemicals can
be adapted to new chemicals for which there
is exposure during pregnancy.
There are several general toxicokinetic data
and modeling needs to make this framework
fully feasible:
• Develop an accessible database of evaluated
age-specific physiological parameters in
humans and animals
• Expand data available on juvenile animal
toxicology and toxicokinetics
• Develop, calibrate, and validate PBTK
model(s) for early life stages
-Submodels for respiratory deposition and 
uptake (particles, gases)
-Case studies
• Chart the development of lung clearance
mechanisms 
• Characterize in utero dosimetry
• Compile data and create model(s) for lacta-
tional transfer of chemicals
• Continue building database on ontogeny of
metabolic enzyme systems
In addition to these general needs, there
may be a variety of chemical-specific data
needs for any individual analysis, depending
upon the extent of toxicokinetic evaluation
the chemical has already undergone and the
degree to which it has been modeled in test
animals and humans.
Toxicodynamic Considerations
in Understanding Children’s
Health Risks from Exposure 
to Environmental Agents 
Complementing the consideration of toxico-
kinetics are the toxicodynamic issues; i.e.,
how to use known dynamic differences in
development to better understand children’s
susceptibility to environmental agents, and
how and when such information could be
used in an overall risk assessment framework
for evaluating children’s health risks.
The term “developmental dynamics” is
used here to describe the biochemical, molec-
ular, cellular, organ, and organism processes
that change throughout development and
that define and characterize the developing
organism at each life stage. Toxicodynamics is
the response of these normal developmental
processes to toxicant exposure. Such alter-
ations need to be considered in both a tempo-
ral and a dose-related context to understand
the immediate and long-term consequences of
such changes.
In this section we a) identify the role of
toxicodynamics in applying the proposed
framework for assessing children’s risks,
b) evaluate life-stage considerations by devel-
opmental organ system, illustrating their sig-
nificance for the respiratory, immune, and
nervous systems, c) discuss developmental
processes and their implications for toxico-
dynamics in children’s risk assessment, and
d) identify several critical data needs. 
Toxicodynamics in the Risk
Assessment Framework
Toxicodynamics is an integral component of
the proposed framework (Figure 1). Table 1
describes for each phase of the risk assessment
process (problem formulation, analysis, and
risk characterization) how developmental
dynamic information could impact risk
assessments for children. We consider the
major contribution of toxicodynamics to be
within the analysis and risk characterization
stages of the overall children’s risk assessment
framework.
The problem formulation stage of the
children’s risk assessment framework provides
an opportunity for the assessor to understand
the purpose and focus of the risk assessment
and can help to define the breadth of the
toxicodynamic assessment. In addition, by
identifying chemicals or chemical classes to be
evaluated, the problem formulation stage pro-
vides critical input regarding potential biolog-
ical systems for consideration (i.e., do we
already know that this class of chemicals is
neurotoxic?). If yes, then speciﬁc dynamic fac-
tors relevant for the developing nervous sys-
tem should be considered in the analysis.
Likewise, if this class of chemicals is known to
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processes, namely, chemicals known to affect
apoptotic processes, then organ systems that
use these dynamic processes should be consid-
ered in the analysis. In addition, because such
apoptotic processes occur at speciﬁc times in
normal development, critical windows of vul-
nerability could be identiﬁed. Thus, both crit-
ical time periods and target organ systems
could be identified for further evaluation
using dynamic information. During problem
formulation, the risk assessor needs to take
into consideration the life stage of the popula-
tion(s) of concern and the specificity of the
agent of concern.
The proposed children’s risk assessment
framework emphasizes the need to connect
toxicodynamic considerations with concurrent
toxicokinetic considerations. For example, to
assess developmental toxicodynamics it is
essential to understand if the parent compound
or a metabolite would be expected to reach
developing tissues. In addition, it is important
to know what dose levels and at what times
such exposures would be expected; hence, the
importance of timing and dosimetry considera-
tions within the analysis phase of the frame-
work. The assessment of toxicodynamics also
informs quantitative considerations in
dose–response and risk characterization.
Early Life Stages and Susceptibility
Data on life stages and critical windows of
susceptibility in development have been sum-
marized and discussed in a number of recent
workshop/workgroup reports and reviews
(Adams et al. 2000; Adkins 2000; Dietert
et al. 2000; Lemasters et al. 2000; Pinkerton
and Joad 2000; Pryor et al. 2000; Rice and
Barone 2000; Selevan et al. 2000; Weiss
2000; Zoetis and Walls 2003). Figure 3 is a
summary of developmental life stages, includ-
ing those early life stages considered in this
article (i.e., preconception through adoles-
cence). Identification of distinct life stages
facilitates identification and characterization
of potential windows of susceptibility. It is
also important to be able to compare life
stages and particular end points and patterns
of dynamic processes across species. In this
discussion we use a series of general, simpli-
ﬁed life-stage events (summarized in Figure 3)
that include conception, embryonic, fetal,
newborn, neonatal, preweaning, weaning,
juvenile, puberty, adolescence, adulthood,
and old age.
Of course, there are a number of different
ways of viewing the period called childhood.
In considering the toxicodynamic processes
involved with the adverse effects of xenobiotic
materials, it is helpful to be aware of the way
different organizations and disciplines have
viewed and subdivided the developmental
periods. 
Categorization of life stages by dietary age
divisions. As an example, the Institute of
Medicine (IOM) of the National Academies
of Science (NAS) is establishing updated
dietary recommendations for nutrients. As
has been the situation with prior guidelines,
the nutrient recommendations are targeted
toward a series of age ranges that correlate
with the physiological demands of normal
growth and development. The age ranges that
are used for the present set of dietary refer-
ence intakes (IOM 1997, 2001; Murphy
et al. 2002), including the newly established
tolerable upper intake levels, divide the child-
hood period into three major life-stage cate-
gories that are then subdivided into narrower
age ranges. The three major developmental
categories are infancy, childhood, and adoles-
cence. Intakes during pregnancy and lactation
are also considered separate categories.
The infancy period is subdivided into the
ﬁrst and second 6 months after birth. Lactation
demands and the age of introduction of solid
foods were considered in establishing this divi-
sion. The childhood period is subdivided into
two periods (1–3 years and 4–8 years). The
adolescent period is divided into two periods
(9–13 years and 14–18 years) based on the
beginnings of puberty and growth demands.
Males and females are treated differently
during the adolescent period.
The IOM dietary age divisions are impor-
tant considerations in risk assessment because
nutrition and food exposure pathways can
have a strong impact on the evaluation of all
environmental effects. Accordingly, it may
become possible to link nutritional status in a
particular age group with toxicant exposure
and manifestation of effects.
Categorization of life stages by behavior
and exposure windows. Likewise, exposure
assessors have identified a different series of
age-related exposure windows based on
age-specific behaviors and physiological
considerations. For example, differences
between toddlers and neonates in exposure to
carpet and ﬂoor, in hand-to-mouth exposure
pathways, and in dietary patterns and expo-
sures are deﬁned by differences in activities as
well as physiological development. Exposure
considerations in developing life-stage cate-
gories are reviewed in the U.S. EPA children’s
exposure factors handbook (U.S. EPA 2000)
and the U.S. EPA risk assessment forum doc-
ument on issues associated with considering
developmental changes in behavior and
anatomy when assessing exposure to children
(U.S. EPA Risk Assessment Forum 2000).
Many other examples of discipline-based
differences in childhood categorizations could
be cited. For instance, child psychologists or
childhood developmental specialists deﬁne life
stages using behavioral landmarks. Although it
was not considered important for the chil-
dren’s risk assessment framework to fully inte-
grate all the various categorical views of
childhood and major developmental periods, it
is important to be aware that these differences
exist among disciplines.
Recognizing categorical overlap between
disciplines. Although general developmental
life stages do not always match the discipline-
specific exposure windows, the differences
should not prevent the examination of
dose–response relationships for critical devel-
opmental end points. They do, however,
highlight the need for the framework to be
robust enough to allow for iterative interac-
tions between exposures and effects analysis in
both the problem formulation and analysis
stages. The overlap of categories also identiﬁes
a need for risk assessment methods that
would allow risk assessors to relate outputs
from the exposure assessments to those from
discipline-speciﬁc assessments using multiple
exposure times during various life stages.
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Table 1. How does developmental dynamic information impact risk assessments for children?
Problem formulation
Determination of risk assessment context and scope
Deﬁnition of scope provides context for risk assessment and leads to the identiﬁcation of relevant life stages,
systems, or processes of interest for the risk assessment
Determination of relevant exposure pathways/scenarios will provide context for identifying relevant 
developmental life stages
Determination of chemical-speciﬁc factors will also provide context for the identiﬁcation of potential life stages 
for evaluation, as it will identify potential toxicological processes of interest and hence identify developmental
systems for potential evaluation
Identiﬁcation of cross-species relevancy of potential responses
Analysis
Identiﬁcation of uniquely susceptible dynamic processes
Identiﬁcation of developmental milestones and/or end points for testing/assessment
Identiﬁcation of functional consequences of processes if altered
Illustrate the interrelatedness of dynamic developmental processes and thus identify impacts that could occur at
later life stages and within other organ systems
Identiﬁcation of immediate or delayed responses
Risk characterization
Deﬁne dose–response relationships, especially dose, time, and response relationships
Characterize potential magnitude of effect, reversibility, repair, functional reserve, etc., of dynamic developmental
processesThus, the timing and dosimetry relationships
shown in Figure 3 become very important for
the hazard/risk assessment equation and
hence linkage with developmental hazard
identiﬁcation and dose–response assessments.
Examples of the Importance of Life-
Stage Considerations
We selected three speciﬁc organs or biological
systems to evaluate and illustrate distinct life-
stage considerations: the immune, respiratory,
and nervous systems. These were chosen to
illustrate the importance of toxicodynamic
considerations for children’s risk and were not
intended to be comprehensive. Many other
organ systems in development would also be
important in this context, including but not
limited to cardiovascular and endocrine
development (Barr et al. 2000). 
Figure 4 shows the initial appearance of
organ systems during gestation in humans
and in rodents. Note that the relative tempo-
ral initial development of each organ system,
defined by the first appearance of cellular
structure of each system, can vary greatly
across species.
Respiratory system. Figure 5 shows the
temporal development of the respiratory sys-
tem in humans and in rodents (Pinkerton
and Joad 2000). The human respiratory sys-
tem involves the formation of a highly
ordered airway branching system with
25,000 distinct terminations giving rise to
more than 300 million alveoli as well as the
differentiation and proliferation of over
40 different cell types. The transition of the
lungs from a simple protruding bud of tissue
from the foregut into a highly organized,
integrated, complex structure that is inner-
vated, ventilated, and vascularized is a multi-
step process. Obvious from Figure 5 is the
fact that although remarkable structural
changes occur during the embryonic develop-
ment such as pseudoglandular, canalicular,
and saccular stages of prenatal development,
changes to the lungs continue into the post-
natal developmental period. Approximately
80% of the alveoli present in the adult lung
are formed after birth. Numerous metabolic
and biochemical functions of the lungs
undergo development and maturation during
the postnatal time frame, which includes the
proliferative period of the alveolar phase of
postnatal lung growth.
Physiologic development of the lungs
continues to increase in large measure during
the period of alveolar expansion in the post-
natal period. The alveolar period of growth
also encompasses further development of the
airways. Although branching morphogenesis
of the bronchial tree is essentially complete
at birth, the airways continue to undergo
maturation, growth, and expansion through
early adulthood.
A number of studies suggest that the
processes of cellular differentiation, branch-
ing morphogenesis, and overall lung growth
can be affected by exposure to chemicals and
particles. Both embryogenesis and fetal ges-
tation represent critical periods of cellular
differentiation and branching morphogene-
sis. The effects of exposure, however, are
likely to be different for each period of
development. For example, during embryo-
genesis and fetal development, cell number,
type, and function of the airways and alveoli
may be significantly affected by exposure to
a diverse number of substances and/or con-
ditions. However, because cells continue to
differentiate and divide during the postnatal
period, chemical exposure during the post-
natal period is also likely to affect the respi-
ratory system, but in a different manner
based on changes in the process of differenti-
ation and morphogenesis (Smiley-Jewell
et al. 1998). As growth is essentially com-
plete by the end of adolescence, exposure to
chemicals and other factors at this time are
likely to have completely different conse-
quences in the adult compared with those
found in children (Fanucchi et al. 1997;
Plopper et al. 1994; Smiley-Jewell et al.
1998).
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Life stages
Study designs:
Prenatal development toxicity study
Developmental neurotoxicity study
Reproduction and fertility study
Dominant lethal
Subchronic/chronic
P
F1
Preconception
Embryo/
fetal
Newborn
preweaning Juvenile Adolescence Adulthood Old age
Death
Senescence
Maturity
Puberty
Weaning
Birth
Conception
Litter size, sex ratio, survival, weight,
gross structure, developmental landmarks
including sexual maturation
Motor activity, auditory startle,
learning and memory,
neuropathology
P estrous cycles, sperm measures,
fertility, pregnancy maintenance,
parturition, organ weight, gross
structure, histology
F1 estrous cycles, sperm measures, fertility,
pregnancy maintenance, parturition,
 organ weight, gross structure, histology
Clinical pathology (every 6 months), ophthalmological exam,
gross and microscopic pathology
Clinical observations,
viability, body weight, food
and water consumption
Neurotoxicity evaluations
F1 sexual
maturation
Embryonic death
Litter size, sex ratio, F1 and F2 survival,
weight, gross structure, brain, spleen,
thymus weights
Functional observations, motor activity,
auditory startle, learning and
 memory, neuropathology
Litter size, sex ratio, fetal survival,
weight, gross structure
Figure 3. Exposures and end points related to developmental toxicity evaluations. Figure adapted from Kimmel (2001).Inhalation exposure to substances during
critical windows of development may have
profound effects that would not be seen if the
same exposure were to occur in the adult.
Because lung development occurs over the
entire prenatal period, exposure effects can
have significantly different consequences
depending upon whether they occur during
the pre- or postnatal period of life. Although
our understanding of these changes at this
time is extremely limited, one would expect
that abnormal developmental changes that
occur in the prenatal period because of expo-
sure to a variety of chemicals may have long-
term effects persisting into adult life.
Examples of altered lung growth or functional
deficits in respiration have been shown to
result from exposure early in organogenesis to
neonatal and adolescent developmental time
periods (Pinkerton and Joad 2000). In con-
trast, structural abnormalities in the lung that
result from exposure to environmental toxi-
cants are believed to be manifested only while
lung morphogenesis is still occurring, i.e.,
including the neonatal but not adolescent
developmental periods. Very recent studies
have suggested that the development of
asthma and immune disorders of the respira-
tory system may result from exposures during
organogenesis as well as throughout neonatal
and adolescent development (Pinkerton and
Joad 2000).
Immune system. The immune system
undergoes a number of key changes through-
out embryonic, fetal, neonatal, and juvenile
development that would be expected to alter
the potential risk from environmental expo-
sure to toxicants. Figure 6 shows a compari-
son of some of these critical changes for
immune system development in humans and
in rodents. Five speciﬁc stages in the develop-
ment of a mature immune system are illus-
trated and include initiation of hematopoiesis,
migration of stem cells and expansion of
progenitor cells, colonization of bone marrow
and thymus, maturation to immunocompe-
tence, and establishment of immune memory.
These speciﬁc stages were chosen as they rep-
resent discrete steps in the formation of the
mature immune system and also represent
periods in which differential vulnerabilities to
immunotoxicants would be anticipated
(Holladay and Smialowicz 2000). Early
embryonic issues concern the location and
source of stem cells to seed the primary
immune organs such as the thymus. The ini-
tiation of hematopoiesis is a benchmark that
signals the appearance of cells necessary to
sustain immune development. Obviously,
exposures occurring before versus after the
beginning of hematopoiesis, the migration of
stem cells and expansion of progenitor cells,
and the emergence of the bone marrow as an
important progenitor cell source might lead
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Figure 5. Respiratory system development in humans and rodents. Discrete maturational windows for pre-
natal and postnatal development are shown using hashed bars and compared for humans and rodents.
These discrete maturational windows represent periods in respiratory system development that may have
differential vulnerabilities to respiratory toxicants (Dietert et al. 2000; Pinkerton and Joad 2000). The solid
bars represent time to these initial maturational stages. Figure reproduced from Faustman et al. (2003) and
reprinted with permission of the Institute for Risk Analyses and Risk Communication at the University of
Washington.
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Figure 4. Initial appearance of organ systems during gestation in humans and rodents. A comparative
timeline for the initial appearance of cellular structure of the various components of each organ system
during gestation is given for humans and rodents. The solid bars represent time to initial appearance,
and the hashed bars represent the time window of appearance of these initial organ systems. Note that
for some complex organ systems, the appearance of many initial structures within that organ may be
over an extended period of development. The connections and maturation for most of these systems
continues until after birth for both species. Figure reproduced from Faustman et al. (2003) and reprinted
with permission of the Institute for Risk Analyses and Risk Communication at the University of
Washington.to differences in the manifestation of impact
or outcome. Other benchmarks include the
formation and innervation of the thymus as
well as the seeding of the thymus by waves of
lymphoid cells. Exposures timed such that
they target different waves of lymphoid cells
important in thymic-dependent T-lympho-
cyte maturation is another area for potential
differential impact. Developmental changes
involving peripheral lymphoid organs such as
the spleen may also be important for consid-
eration of the timing of exposures compared
with risk of immunotoxicity.
These events are all initiated prior to birth
in rodents and humans. However, postnatal
processes are also important for complete mat-
uration. These immune developmental stages
could also provide windows of differential
immune sensitivity to toxicants when com-
pared with exposure of the fully matured adult
immune system. Among changes occurring
largely during the postnatal period in rodents
and humans are the maturation to complete
immunocompetence and the establishment of
immune memory.
An example of differential immune system
outcome based on the life stage in which
exposure occurred is seen in studies evaluating
Pb. The heavy metal Pb is a known immuno-
toxicant capable of producing numerous
immune changes including depression of cell-
mediated immunity. A hallmark of Pb-
induced immunotoxicity in adult rodents is
suppression of the delayed-type hypersensitiv-
ity (DTH) response (McCabe et al. 1999).
This functional change is likely linked to the
capacity of Pb to shift immune response capa-
bilities away from Th1 ( helper type-1 T cell)-
dependent responses toward Th2-dependent
responses (Heo et al. 1997; McCabe and
Lawrence 1991). Exposure of rats throughout
gestation to levels of Pb that do not alter
maternal immune function can produce per-
sistent depression of the DTH response in
both juvenile and adult offspring (Bunn et al.
2001a; Chen et al. 1999). However, the tim-
ing of exposure appears to be an important
factor. Pulsed exposure of dams to Pb during
late gestation (days 15–21) results in offspring
with depressed DTH response function (simi-
lar to the complete gestational exposure). The
same Pb exposure earlier in gestation (days
3–9) fails to alter DTH response function in
the offspring (Bunn et al. 2001b). 
These findings of temporally dependent
differential immunotoxic outcome have been
extended to other species. For example, expo-
sure of chickens in ovo to a single administra-
tion of Pb on embryonic day 12 causes
depressed DTH function in juvenile chick-
ens. However, exposure of embryos to the
same level of Pb only 3 days earlier, produc-
ing identical blood Pb levels at hatching, fails
to alter DTH function in the offspring (Lee
et al. 2001). It has been hypothesized that the
development of the thymus may be key to
these differential effects after Pb exposure.
This example suggests that comparable envi-
ronmental exposures during different win-
dows of development have the potential to
produce qualitative differences in immune
system outcomes.
Nervous system. Figure 7 shows a com-
parison of nervous system development in
humans and in rodents. After neurogenesis
each neuronal cell continues to mature
through a process of migration, settling to a
speciﬁc location and extending projections to
a designated target site. In many cases such as
for the external germinal layer, this process of
migration continues well after birth and in
the human can continue for 7 months to
2 years after birth. Earliest synapses develop
during the embryonic period, and by
10 weeks immature synapses are present.
Cortical synapses at birth are still immature
and in the human the morphological charac-
teristics of maturity are reached between 6
and 24 months after birth. The full func-
tional maturation of synapses may be related
to the elimination of unnecessary synapses.
Myelination occurs ﬁrst in the spinal cord by
the end of the first trimester in the human
and proceeds in a caudocranial fashion. At
birth the brain is immature with regard to
the extent of myelination, with prominent
myelination present in the brain stem, cere-
bellar white matter, posterior limb of the
internal capsule, thalamus, and the basal
nuclei. In the human, the rate of myelin
deposition is the greatest in the first 2 years
after birth. In the rodent this is comparable to
the first 35–40 days of life. Nervous system
malformations can arise from alterations of
neurogenesis, changes in the timing of migra-
tion, and perturbation of migratory mecha-
nisms and synaptic development.
Excellent examples exist that demonstrate
concordance of functional changes in behav-
ior across primates and humans when appro-
priate age-speciﬁc comparisons are conducted
(Paule et al. 1988; Slikker et al. 2000). For
example, performance of behavioral tasks in
humans and primates that are designed to
monitor learning, short-term memory, color
and position discrimination, time perception,
and motivation are indistinguishable.
Depending upon task and end point, the
behavior of young adult monkeys is identical
to that of children over the age range of
4–12 years. Of significance is that perfor-
mance on many of these tasks is highly corre-
lated with IQ in children (Paule et al. 1999a).
Interesting age-related effects have been seen
in functional outcomes for the nervous sys-
tem. For example, chronic marijuana smoke
exposure in peripubescent male monkeys
resulted in an amotivational-like syndrome
similar to that reported for human subjects
(teenagers or young adults only—never
reported for mature adult humans) (Paule
et al. 1999b; Schulze et al. 1988).
Lessons learned from life-stage examples.
Several observations can be made based on
these examples. First, for each biological system
there were multiple windows of susceptibility.
Second, windows of susceptibility were fre-
quently identified throughout childhood. In
fact, for many cross-species comparisons, birth
was a rather arbitrary milestone in the develop-
mental process. Third, the windows of suscep-
tibility were deﬁned upon the basis of distinct
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Figure 6. Immune system development in humans and rodents. A comparison of critical stages for immune
system development is shown for humans and rodents. Hashed bars represent discrete development
steps in the formation of the mature immune system and represent periods where differential susceptibili-
ties to immunotoxicants could be expected (Holladay and Smialowicz 2000). Solid bars show time to “sen-
sitive window” in each species. Figure reproduced from Faustman et al. (2003) and reprinted with
permission of the Institute for Risk Analyses and Risk Communication at the University of Washington.development processes and many of these
processes were common across windows for
different biological systems (e.g., apoptosis rel-
evant for both neurological and immunological
development).
Even with the limited number of systems
evaluated, it is apparent that large data gaps
exist in the completeness of our understand-
ing of these processes and particularly in iden-
tifying which developmental windows
represent real or hypothesized windows of
susceptibility. The lack of functional data
complicates interpretation of animal-to-
human comparisons and precludes the trans-
lation of developmental observations into
public health–relevant end points.
An End Point Example: Cancer
Another way to look at the impact of life
stage on toxicity is by focusing on an end
point rather than an organ or functional sys-
tem. Some data from animal studies are avail-
able on cancer susceptibility across life stages.
In the monograph from a previous ILSI
workshop, McConnell (1992) compared out-
comes of cancer bioassays conducted at vari-
ous exposure times throughout gestation. In
general, conclusions from such reviews were
that usually the timing of exposures did not
affect tumor type (no qualitative differences),
but quantitative differences in dose–response
relationships and the incidence of tumors
were observed. However, a disclaimer was
given that there was a limited number of
studies, with few chemicals tested in a consis-
tent manner at varying times across gestation
and postnatal developmental periods. That
observation was essentially reconfirmed by
another ILSI RSI working group focusing on
research needs (ILSI RSI 1996). Thus, a com-
prehensive database from which to make a
comparative evaluation is still lacking.
An important exception to this generalized
statement is the example of acute T-lympho-
cytic leukemia. A high percentage of these
leukemias is due to a V(D)J recombinase-
mediated deletion (tald) or translocation
(t-1:14) that can occur only in the fetus or in
children (Finette et al. 1997). Somatic cell
gene mutations that arise through an aberrant
differentiation process are limited to cell or life
stages where the process is normally operative.
An example is the V(D)J recombination
mechanism that normally functions to
rearrange variable (V), diversity (D), and junc-
tional (J) regions of immunoglobulin (Ig) and
T-cell receptor (TCR) genes in B and T
lymphocytes, respectively. B cells differentiate
in the bone marrow throughout life in
humans. However, normal T-cell differentia-
tion is limited to the thymus gland in fetuses
and children and is complete by late adoles-
cence. Aberrant functioning of the V(D)J
recombinase mechanism may be induced by
environmental agents such as passive exposure
to tobacco smoke (Finette et al. 1997). This
results in rearrangements of genetic segments
other than those of the Ig or TCR genes in
developing lymphocytes. Some of these aber-
rant rearrangements constitute the chromo-
some deletions and translocations that
characterize lymphoid malignancies. Thus,
qualitative differences in cancer outcome are
possible after age-specific alterations (c.f.,
Olshan et al. 2000).
Developmental Processes and
Interactions
Developing tissues and organs, especially
during the prenatal stages of life, participate in
common complex interactions that permit,
encourage, and control cellular processes.
These dynamic processes include differentia-
tion, proliferation, migration, secretion, and
apoptosis. As an example, Figure 8 shows the
temporal differences in one of these processes
(proliferation) across various brain regions dur-
ing nervous system development in the mouse.
A different temporal pattern would be seen if
apoptosis were plotted against brain regions; in
some regions it appears simultaneously with
proliferation, and in some brain regions it
appears at a later developmental time.
For the most part, those tissue populations
that engage in developmentally important
interactions share a set of characteristics,
which may make them vulnerable to perturba-
tions by outside inﬂuences. The set of charac-
teristics includes the following:
• Populations of cells interact, as opposed to
individual cells.
• The interacting populations of cells experi-
ence developmentally different histories;
that is, they experience divergence in their
differentiation pathways.
• The interacting populations are in proximity
to each other.
• One population of cells (e.g., the inducer)
transmits a message of developmental
importance (usually considered to be a sig-
nal molecule) during a ﬁnite period.
• The second (responding) population of cells
must be capable of receiving and responding
to the signal (i.e., must be competent); the
state of competence is maintained for a
ﬁnite period of time. 
The latter three characteristics involve one
of the signal transduction pathways. A recent
report by the NRC (2000) has identified
17 signal transduction pathways that are
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Figure 7. Nervous system development in humans and rodents. Each set of hashed bars represents the
time of origin for each structure of the nervous system. Solid bars represent time to structural develop-
ment for each nervous system structure (Rice and Barone 2000; Rodier 1977). After neurogenesis each cell
continues to mature through the process of migration, settling to a speciﬁc location and extending projec-
tions to designated target sites. In many cases such as for the external germinal layer, this process of
migration continues well after birth and in the human can continue for 7 months to 2 years after birth.
Figure reproduced from Faustman et al. (2003) and reprinted with permission of the Institute for Risk
Analyses and Risk Communication at the University of Washington.highly evolutionarily conserved across multi-
ple phyla and that appear to be able to explain
most if not all relevant signaling pathways in
development. The developmental process
may be derailed by a) disruption of these
steps by altering the length of the period for,
or timing of, induction or competence so that
they are not contemporaneous; b) diminish-
ment of the amount of available developmen-
tal message; c) interference with reception of
the message; or d) prevention of appropriate
activity by the responding tissue. The impor-
tance of many of these pathways has been
illustrated with genetically sensitized test
organisms or transgenic animal models.
Because developing tissues and organs rely on
such complex, temporally orchestrated inter-
actions (see this orchestration in Figure 8 for
just one of these dynamic processes, prolifera-
tion), they are exquisitely sensitive to pertur-
bations of their environment. Additionally,
because normal development proceeds from a
cascade of such orchestrations, developmental
processes are far more vulnerable to environ-
mental vicissitudes than are stable, mature tis-
sues. Furthermore, as maturation proceeds,
the impact of small environmental challenges
becomes increasingly subtle. This contributes
to the difficulty in recognizing the effects of
environmental challenges on differentiation
processes that occur after most gross morpho-
logical structures have been established.
Impacts of modiﬁcations in histological archi-
tecture are often manifested as changes in
function and as such are more difficult to
detect than alterations that occurred early in
development, which are often manifested as
gross malformations.
The process of development has an inher-
ently dynamic nature, and developing systems
possess and exercise multiple signaling path-
ways simultaneously. Furthermore, many of
the pathways exert overlapping functions,
especially in mammalian species. As discussed
by the National Research Council (2000),
this redundancy has contributed to both the
plasticity of developing organisms to develop
normally after challenges and also has been
the reason for failure of some of the knockout
models. Consequently, it is important that
the developmental consequences of perturba-
tion of any of the signaling pathways be
determined and that the changes not be
viewed in isolation. In Figure 9, a diagram
from the National Research Council 2000
report portrays the fact that such cell-signal-
ing processes occur at the molecular,
organelle, and cellular levels but must be put
into a broader context of organ, tissue, and
conceptual development as well as a kinetic
and dynamic context to understand both
dose–response relationships and ultimate
impacts on developmental outcome.
Application of Information on Life
Stage and Toxicodynamics
So how can knowledge of life stage–specific
toxicodynamics inform risk assessment for
children? First, as illustrated for several sys-
tems and end points, an understanding of the
timing and cross-species comparison of the
developmental processes occurring during
various life stages would inform the hazard
characterization processes by identifying
potentially unique times and organ systems
during development. This information could
suggest speciﬁc organ systems and functional
impacts that might occur if exposures were to
occur during those life stages. This informa-
tion would also suggest the need to evaluate
the potential hazard in specific types of ani-
mal tests (Figure 3) and would provide some
cross-species context for hazard characteriza-
tion. It could also provide some mechanistic
basis for evaluating impacts of the test agent
on isolated developmental processes such as
apoptosis and differentiation. Of particular
importance is that life stage–specific assess-
ment of health effects would more easily
allow the assessor to link and evaluate the
potential for subsequent functional alter-
ations. Understanding the temporal and
physiological interrelatedness of developmen-
tal processes would allow the evaluator to
better anticipate health impacts in other
biological systems and to better forecast or
evaluate impacts at later life stages.
Toxicodynamics informs our under-
standing of toxic mechanisms and mode of
action (Faustman et al. 1997, 2000). The
case of atrazine illustrates the fact that
knowledge of developmental dynamics can
make a difference (U.S. EPA 2002). Atrazine
is the most commonly detected pesticide in
ground and surface water, given the volume
of usage and tendency to persist and move
with water. The major exposure pathway is
through drinking water, and there are
episodic peaks of exposure. Other pathways
for exposure are through food (minimal) and
in residential applications (dermal/inhala-
tion). Atrazine has been shown to cause
mammary tumors in Sprague-Dawley rats.
Given the endocrine target organ site in the
rodent bioassay (i.e., mammary gland
tumors), studies were undertaken to deter-
mine whether a neuroendocrine mode of
action was involved. It was concluded that
the mammary tumors in this strain are not
relevant for humans. However, the finding
of disruption of the neuroendocrine system
raised concerns for potential effects on the
development and maintenance of the repro-
ductive system. Subsequent studies showed
that the compound alters ovarian function
(cyclicity), disrupts critical reproductive
processes, including delaying puberty [males:
postnatal days (PNDs) 23–53; females:
PNDs 22–45), pregnancy loss (gestational
days 6–10), decreased dam prolactin release,
and prostatitis in offspring (PNDs 1–4), and
has effects on lactation (milk quality/produc-
tion). Atrazine is thus a good example of a
compound whose mode of action in an ani-
mal model was useful in highlighting the
need to examine specific potential target
organs and life stages.
In addition, toxicodynamics could provide
quantitative information relevant for assessing
dose response, especially dose and time
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Figure 8. Patterns of neuronal proliferation in speciﬁc brain regions of mice. Illustration of overall mouse
brain development showing critical windows of peak neuroepithelial cell proliferation (neurogenesis)
within speciﬁc brain regions and nuclei throughout gestation. Figure reproduced from Rodier (1977) and
reprinted with permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc.relationships. It could also begin to inform our
assessments of acute versus chronic exposure
impacts. It would also provide some context
for linking potentially susceptible tissues with
kinetic proﬁles to provide a basis for evaluat-
ing kinetic measurements of target-tissue
doses. For example, an understanding of the
underlying temporal relationships for the
dynamic processes occurring in development
would inform kinetic measurements such as
determining whether AUC or peak in utero
concentrations of the toxicant or metabolite
are more important for our risk analysis.
An example of where life stage-specific
exposure information has had an impact on
quantitative dose–response assessments is seen
in cases of pre-, post-, and neonatal carcinogen
exposure. Anderson et al. (2000), for example,
summarized published literature for transpla-
cental and neonatal carcinogens by target tis-
sue and time of exposure for chemical and
radiation exposures and discussed a number of
factors hypothesized as determining suscepti-
bility to carcinogenic insult at different
developmental stages. These susceptibility-
deﬁning factors include 
a) numbers of target cells at risk, b) sensitivity to
cell killing, c) effects of rate of cell division. . . ,
d) ability to repair DNA damage, e) expansion of
clones of mutated cells. . . , f) presence of undiffer-
entiated stem cells, g) development of differenti-
ated characteristics, including ability to carry out
metabolic activation, h)m etabolic detoxification
by placenta and/or maternal tissues, and i) meta-
bolic detoxiﬁcation by the perinate itself. . . .
The article cites experimental evidence
for each of these factors. Increasing under-
standing of how all these factors can impact
qualitative and quantitative tissue and species
specificity is needed; however, compelling
examples exist for quantitative differences.
For example, “in patas monkeys transplacen-
tal N-ethyl-N-nitrosourea caused more
tumors than the same dose given to juvenile
monkeys, confirming the quantitatively
higher sensitivity of the fetuses seen for this
chemical in rodents” (Anderson et al. 2000;
Rice et al. 1989).
Because tumor incidence determines the
slope of the dose–response curve and the Q*
value (an upper bound on the slope of a can-
cer dose–response curve), a Q* derived from
an adult animal study will have a ﬂatter slope
than that which would be derived from a
study that incorporated dosing of the neona-
tal animal where tumor incidence is higher.
The practice of amortizing exposure to a car-
cinogenic compound has the effect of lower-
ing the much higher dose that children may
receive during the first years of life. Taken
together, the use of a Q* value that does not
accurately represent the slope of the
dose–response curve for young animals and
the effect of amortizing children’s doses may
result in a cancer risk assessment that is not
adequately protective of children.
Critical Data Needs
Some specific data needs and questions are
highlighted here as being particularly critical
to an improved application of toxicodynamic
principles in assessing risks for the developing
human. These critical data needs include
• An improved understanding of the meaning
(signiﬁcance) of subtle effects (biomarkers)
and validation of their relevance for risk
assessment
• Ability to link assessments to more robust
functional end points
-Development of more end points for 
assessing system function that can be used
in both humans and animals. This is a
major issue, as the absence of these tools is a
huge impediment to actually assessing the
effects of exposure. Imaging techniques
could be very valuable as well, especially
functional magnetic resonance imaging. 
-Resources for animal-to-human correlation
• Better understanding of the toxicodynamics
of public health–relevant end points, such as
asthma and cardiovascular disease
• Comparison of the toxicodynamic links
between the effects of acute, subchronic,
and chronic exposures
• Better characterization of the development
of homeostatic set points for many physio-
logical systems
• Better understanding of repair, tolerance,
and hypersensitivity in animal and human
responses
• More and better diagrams across life stages 
-There needs to be a concerted effort in 
comparative biology/physiology to develop 
tables or other references for easily identi
fying analogous periods in development 
across species. 
• More epidemiology studies that encompass
multiple life stages (including early/develop-
mental periods).
In addition, there is a need for multidisci-
plinary training for work in children’s health at
all levels (graduate students, postdoctoral
researchers, scientists in the ﬁeld) and for more
multidisciplinary workshops and interactions
on the assessment of children’s health risks.
Summary
There are distinct life stages evident across
development, with both known and hypothe-
sized windows of susceptibility. These various
life stages are based on differences in develop-
ment defined by differences in relevant
dynamic processes occurring at the molecular,
cellular, organ, and physiological level, and
these differences may deﬁne in what systems
and at what magnitude an environmental
impact will be manifested. There can be
apparent species differences in response to
environmental exposures if the dynamic
processes are not compared at equivalent
doses and time points across species.
Differences in developmental dynamic
processes can impact all stages of the proposed
children’s risk assessment framework, as well
as all components of the traditional risk assess-
ment paradigm. Common dynamic processes
can impact susceptibility. For example, con-
sideration of impacts on apoptosis versus
migration could provide clues as to what bio-
logical systems may be affected and at what
times these impacts would be identifiable.
There are also implications for animal testing,
and some ways to improve our understanding
of dynamic processes across species, dose, and
life stage have been discussed. Finally, there
is a need to improve our assessment of
functional and public health–relevant effects
in our testing approaches.
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Figure 9. Levels of mechanistic inquiry for assessing the effects of a toxicant on development. Figure
reproduced from NRC (2000) and reprinted with permission by the National Academy of Sciences, cour-
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the Framework
Risk characterization, as the ﬁnal step in the
process of assessing children’s risks, cannot
succeed unless the inputs from the preceding
steps are appropriately directed at the prob-
lems associated with risks during childhood.
Our definition of the life stages encom-
passed in the term “childhood” is broader
than a dictionary definition. It encompasses
not only life after birth but also embryonic
and fetal development. Our definition is
rooted in the concept that special risks to chil-
dren are the result of actions of toxicants on
developmental processes, leading to different
mechanisms and/or manifestations of toxicity
than in adults. These unique mechanisms and
outcomes arise because the individual is devel-
oping; birth, while signiﬁcant, does not mark
the end of development or of the capacity for
an agent to produce permanent, organiza-
tional effects on function. Therefore, from
the context of developmental biology and tox-
icology, children’s risk assessment is really
developmental risk assessment, and as such
must include the developmental stages that
take place before birth.
There is abundant literature spanning
many decades demonstrating the unique sus-
ceptibility of the embryonic period to struc-
tural teratogens. The thalidomide tragedy of
the late 1950s and early 1960s demonstrated
to the world that an agent can have radically
different effects in the embryo than in the
adult and that these effects may be perma-
nent. Research on the developmental toxicity
of lead or ethanol, to name two examples,
demonstrates that the fetal and neonatal peri-
ods are also sensitive, with manifestations of
toxicity being largely functional in nature
with few obvious structural correlates.
Epidemiologic evidence indicates that early
menarche increases the risk for breast cancer;
there is the potential for agents with estro-
genic activity to accelerate puberty and, pre-
sumably, the risk for later effects. These are
just a few examples of the unique susceptibili-
ties of developing life stages (c.f., Landrigan
et al. 2004 ).
But are these susceptibilities the result of
mechanisms of toxicity that are themselves
unique to the developing organism? There are
clear examples in which the outcomes of expo-
sure are radically different in developing life
stages than in adults, so much so that the
nature of the outcomes could not be predicted
from observations in adults or experiments in
mature animals. Whether these are attribut-
able to different mechanisms of action is
unanswerable at this point because we have
too little information about toxic mechanisms,
particularly during development. It is reason-
able to assume that there probably are mecha-
nisms of action specific to development,
whereas in other cases the mechanism may be
the same as in adults but with a different out-
come. For example, it appears clear that the
effects of retinoic acid are mediated through
retinoic acid receptors in embryos and adults,
but the teratogenic outcome of retinoic acid
exposure in the embryo is not at all similar to
adult intoxication. Because of this, the possi-
bility of unique developmental outcomes
makes the problem of children’s hazard
identification and risk characterization an
important one, irrespective of whether the
mechanisms of action of a toxicant are the
same as in an adult.
In the proposed framework for children’s
risk assessment (Figure 1), the problem for-
mulation step focuses on the interrelation-
ships among exposures, effects, and host
factors. These considerations are consistent
with the way epidemiologic data are collected
and directly feed into the hazard characteri-
zation and exposure assessment steps of the
classical risk assessment paradigm. Host con-
siderations will include the life stages of con-
cern in the assessment and also any factors
that are speciﬁc to a given situation, namely,
genetic, nutritional, or socioeconomic factors
that may influence biological response or
extent of exposure.
The end result of problem formulation is
the development of a conceptual model
describing the problem and indicating the
possible risk assessment options. This model
then guides the analysis phase. The analysis
phase consists of characterizing life stage–
speciﬁc exposures and health effects, namely,
the content of exposure assessment and haz-
ard characterization. The linkage between
these two is a consideration of timing of
development and exposure, and dosimetry.
Toxicodynamics forms the basis for life
stage–specific hazard characterization, and
toxicokinetics is the underpinning for charac-
terization of the timing of target-tissue
exposures and dosimetry.
The purpose of the analysis phase is to
produce an adequate basis for risk characteri-
zation. It is possible for the analysis phase to
fail because of an inadequate conceptual
model, in which case the framework allows
for iterative refinement of the model and
reentry into the analysis phase.
Risk characterization consists of a life
stage–speciﬁc consideration of risk combined
with uncertainty and variability analyses,
which culminates in a narrative statement
describing the nature of the risk, its likeli-
hood under speciﬁc scenarios, and the degree
of uncertainty in and confidence in the
assessment. Risk assessors need to be explicit
in categorizing uncertainty and variability
and evaluate the use of uncertainty factors
versus other methods for estimating and
incorporating variability into the assessment. 
The most straightforward way to
determine whether there are differences
between adult and developmental responses
to an agent is to test for developmental effects
in appropriate models and to acquire life
stage–specific exposure information. The
question of whether an additional uncertainty
factor should be used is one that must be
determined on a case-by-case basis, using a
weight-of-evidence evaluation of existing
data. If there are no data, or the database is
deficient, then this uncertainty needs to be
addressed, for example, by generating more
data or by using the uncertainty factor already
in place at the U.S. EPA for accommodating
database deficiencies. The magnitude of the
uncertainty factor(s) depends on a variety of
factors associated with the database and
should be assigned using a weight-of-evidence
approach. Chronic, cumulative, or irreversible
effects tend to be of greater concern. 
Of course, there can be multiple sources of
child-speciﬁc uncertainty. These can include
anything from the comprehensiveness of the
exposure and toxicology databases to the
appropriateness of the animal model used or
the strength of epidemiologic data. Only by
learning more about human biology, includ-
ing the potential range of responses and more
about the capacity (and limitations) of animal
and other experimental models to predict
effects in humans, can we expect to alleviate
the uncertainty represented by the uncertainty
factors used in risk assessment. It should be
possible to develop minimum criteria to sup-
port a good risk assessment (Moore et al.
1995). Certainly, it needs to be acknowledged
that additional data may increase or decrease
the reference dose for a compound. Finally, it
should be noted that there are already policies
in place to accommodate database deﬁciencies.
In the end, it is clear that the full spec-
trum of potential developmental effects can-
not be predicted from adult data; therefore, a
core data set in developing organisms is
needed. Adequacy of the data set to assess the
potential for risk to children should be deter-
mined after existing data on exposure (both
known and anticipated scenarios) and effects
are described and summarized. The overall
vision for risk characterization is a meaning-
ful, life stage–linked probabilistic calculation
of risk.
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